Viral Vectors & Plasmid DNA Manufacturing Market to Hit US$ 1.3 Bn by 2027

19 Aug 2021
www.globenewswire.com
Gene TherapyCell TherapyVaccine
Ottawa, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Ottawa, Aug 19, 2021 (GLOBE NEWSWIRE) – According to Precedence Research, the viral vectors & plasmid DNA manufacturing market size was valued at US$ 319.01 million in 2019. Drivers Market Restraints Opportunities Gene therapy is an experimental treatment that comprises incorporating genetic material inside a person’s cells to stopor fight a particular disease. Researchers are studying gene therapy for several diseases including hemophilia, cancer, Parkinson's disease, severe combined immuno-deficiencies, HIV, via numerous dissimilar methods. A gene can be carried to a cell with the help of a carrier known as a vector. Viruses are the most generalkinds of vectors used in gene therapy. Since last few years, several non-viral and viral vectors have been standardized and enhanced. Report is Ready, Immediate Delivery after Payment | Get the Sample Pages of Report@ At present, the much wide spread viral vectors utilized for gene therapies are those based on lentivirus, retrovirus, adenovirus, and AAV vectors. These correspondingly form 8%, 16%, 20%, and 8% of the clinical trialsof active gene therapy. Likewise, plasmid DNA has appeared as the most frequently preferred vectors amid non-viral gene delivery tools. Further, it finds application in production and development of DNA vaccines and viral vectors. There is growing demand for practical manufacturing solutions for viral vectors that can be freely scaled and boosted. This is because gene and cell therapies possess latent to quickly advance via clinical trials to commercialization.With the help of ongoing efforts, several organizations are respectivelyexecutingand developing state-of-the-art solutions intended to scale-up for viral vector manufacturing and speed up process development. Global Market Revenue (USD Million) and Growth Rate Comparison by Workflow (2016-2027) Growth Factors Viral vectors have become ideal choice for gene transferdue to their efficient gene delivery, high transfection efficiency and stable gene expression. Further, upsurge in registration of clinical trials on viral vector-mediated gene therapy is stimulating inclination for viral vectors in gene transfer. Growing pervasiveness of target disorders and diseases, the accessibility of funding for gene therapy development, current research into viral vector-based cell and gene therapies and efficacy of viral vectors in gene therapy delivery are together supporting the market growth. Unexploitedlatent in emergent markets is projected to provideworthwhile growth opportunities for participants in this market. Furthermore, groundbreaking development in the vaccinology is fuelling the demand of these vectors to greater extent. Great amount of clinical and preclinical studies assessing the prospective of vectors in these cutting-edge therapies haveexhibitedfavorable results. As a result of this,several investors are attracted towards this area which is making plasmid and viral vector manufacturing market avigoroussector of investment. Further, it is inspiringfortunate funding activities from both the public and private sectors. Report Highlights Get Customization on this Research Report@ Key Players & Strategies Several established organizations have been involved in the production of vectors since the inception of this domain. However, the growing demand for these programs has spurred the establishment of many start-ups as well. Examples include (indicative list, in alphabetical order) Batavia Biosciences, Brammer Bio, GenIBET Biopharmaceuticals, Immune Technology, Lentigen Technology, Luminous Biosciences, Oxford Genetics, SignaGen Laboratories, Vectalys and Virovek. It is also worth highlighting that over 50 academic institutes / non-profit organizations are currently involved in the production of vectors for use in gene therapies. The demand for clinical grade and research vectors is much than commercial grade vectors and almost many gene therapy entrants are in development stage. Nevertheless, some companieshave are rigorouslymanufacturing commercial scale capacity for vector production. Some of these players includeBioReliance, Aldevron, Eurogentec, Cobra Biologics, Lonza, MassBiologics, FUJIFILM Diosynth Biotechnologies and WuXiAppTec amongst others. Market Segmentation By Vector Type By Application By Workflow By End-User By Disease By Geography Full Report is Ready and Can be Dispatched You Immediately After Payment Confirmation | Buy this Premium Research Report@ You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com | +1 9197 992 333 About Us Precedence Research is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defense, among different ventures present globally. For Latest Update Follow Us:
Organizations
Indications
Targets
-
Drugs
-
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.